WeTrade's Monkeypox Test Kit Sales Top $50 Million As Shares Soar

  • Software-as-a-services (SAAS) and cloud intelligent systems provider WeTrade Group Inc WETG forged an agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests for $50 million.
  • Parkway Medical agreed to purchase 5 million units of the nucleic acid test (RT-LAMP) and 6 million units of antigen tests (Colloidal Golden Technique) for $50 million.
  • Parkway Medical has paid $1 million as a deposit.
  • CEO Pijun Liu commented, "It is important for us to be efficient so that we can take the lead to effectively tackle the challenges of the monkeypox outbreak."
  • Earlier WeTrade collaborated with Jiqing Biomedical Technology Co Ltd to produce and provide exclusive sales channels for monkeypox virus test kits and antigen tests.
  • Price Action: WETG shares traded higher by 35.40% at $19.48 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsMoversTechTrading IdeasBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!